Presence of variable extrathoracic airflow limitation in patients with a negative methacholine challenge test.

IF 2.6 4区 医学 Q2 ALLERGY Allergy Asthma and Clinical Immunology Pub Date : 2023-11-29 DOI:10.1186/s13223-023-00860-w
Zane Z Elfessi, Sarah Zavala, Israel Rubinstein
{"title":"Presence of variable extrathoracic airflow limitation in patients with a negative methacholine challenge test.","authors":"Zane Z Elfessi, Sarah Zavala, Israel Rubinstein","doi":"10.1186/s13223-023-00860-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Determine whether variable extrathoracic airflow limitation (VEAL) is observed in patients with negative methacholine challenge tests (MCT).</p><p><strong>Methods: </strong>Electronic medical records of patients undergoing MCT at Jesse Brown VA Medical Center between January 2017 and December 2019 were reviewed. Only patients with negative MCT were selected. Pertinent demographic, clinical, and pulmonary function tests (PFT) and MCT data were abstracted from each record. Spirometric flow-volume loops recorded during each test were inspected by one co-author to determine the first inhaled methacholine concentration at which FEF<sub>50</sub>/FIF<sub>50</sub> was either > 1 or further increased if baseline FEF<sub>50</sub>/FIF<sub>50</sub> after nebulized saline (vehicle) already exceeded 1. Student's t-test was used for statistical analysis. P < 0.05 was considered statistically significant.</p><p><strong>Results: </strong>One hundred and twenty-seven consecutive patients with normal baseline PFT and negative MCT were identified. Thirteen patients (10.2%) had negative MCT and FEF<sub>50</sub>/FIF<sub>50</sub> > 1 after testing. They were predominately obese (BMI, 31.3 ± 6.6), non-smoking (10), White (8) males (9) aged 51.3 ± 14.1 years (mean ± SD) referred for symptoms suggestive of asthma (n = 7) or for chronic cough (n = 6). Five had obstructive sleep apnea, three gastroesophageal reflux disease, and two chronic rhinosinusitis. FEF<sub>50</sub>/FIF<sub>50</sub> increased significantly from 0.72 ± 0.21 after nebulized saline (vehicle) to 1.21 ± 0.13 after inhaled methacholine (p < 0.001). Median inhaled methacholine concentration eliciting these responses was 1.0 mg/mL (range, 0.25-16 mg/mL).</p><p><strong>Conclusions: </strong>VEAL is observed in a subset of patients with a negative MCT. This phenomenon should be recognized and reported to the referring healthcare providers and its clinical significance addressed as indicated.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"19 1","pages":"101"},"PeriodicalIF":2.6000,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687982/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy Asthma and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13223-023-00860-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Determine whether variable extrathoracic airflow limitation (VEAL) is observed in patients with negative methacholine challenge tests (MCT).

Methods: Electronic medical records of patients undergoing MCT at Jesse Brown VA Medical Center between January 2017 and December 2019 were reviewed. Only patients with negative MCT were selected. Pertinent demographic, clinical, and pulmonary function tests (PFT) and MCT data were abstracted from each record. Spirometric flow-volume loops recorded during each test were inspected by one co-author to determine the first inhaled methacholine concentration at which FEF50/FIF50 was either > 1 or further increased if baseline FEF50/FIF50 after nebulized saline (vehicle) already exceeded 1. Student's t-test was used for statistical analysis. P < 0.05 was considered statistically significant.

Results: One hundred and twenty-seven consecutive patients with normal baseline PFT and negative MCT were identified. Thirteen patients (10.2%) had negative MCT and FEF50/FIF50 > 1 after testing. They were predominately obese (BMI, 31.3 ± 6.6), non-smoking (10), White (8) males (9) aged 51.3 ± 14.1 years (mean ± SD) referred for symptoms suggestive of asthma (n = 7) or for chronic cough (n = 6). Five had obstructive sleep apnea, three gastroesophageal reflux disease, and two chronic rhinosinusitis. FEF50/FIF50 increased significantly from 0.72 ± 0.21 after nebulized saline (vehicle) to 1.21 ± 0.13 after inhaled methacholine (p < 0.001). Median inhaled methacholine concentration eliciting these responses was 1.0 mg/mL (range, 0.25-16 mg/mL).

Conclusions: VEAL is observed in a subset of patients with a negative MCT. This phenomenon should be recognized and reported to the referring healthcare providers and its clinical significance addressed as indicated.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
甲胆碱激发试验阴性患者存在可变胸外气流限制。
目的:确定甲胆碱激发试验(MCT)阴性患者是否存在可变胸外气流受限(VEAL)。方法:回顾Jesse Brown VA医疗中心2017年1月至2019年12月期间接受MCT治疗的患者的电子病历。只选择MCT阴性的患者。从每个记录中提取相关的人口统计学、临床和肺功能测试(PFT)和MCT数据。在每次测试中记录的肺量计流量-体积循环由一位合著者检查,以确定首次吸入的甲胆碱浓度,当FEF50/FIF50 > 1时,或者当雾化生理盐水(载药)后的基线FEF50/FIF50已经超过1时,则进一步增加。采用学生t检验进行统计分析。结果:127例基线PFT正常而MCT阴性的连续患者被确定。13例(10.2%)MCT阴性,FEF50/FIF50 > 1。主要为肥胖(BMI, 31.3±6.6),不吸烟(10),白人(8),男性(9),年龄51.3±14.1岁(平均±SD),有哮喘症状(n = 7)或慢性咳嗽(n = 6)。5人患有阻塞性睡眠呼吸暂停,3人患有胃食管反流病,2人患有慢性鼻窦炎。FEF50/FIF50从雾化生理盐水(对照)后的0.72±0.21显著增加到吸入甲胆碱后的1.21±0.13 (p)。应认识到这种现象并将其报告给转诊的医疗保健提供者,并按所述处理其临床意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.30
自引率
3.70%
发文量
96
审稿时长
12 weeks
期刊介绍: Allergy, Asthma & Clinical Immunology (AACI), the official journal of the Canadian Society of Allergy and Clinical Immunology (CSACI), is an open access journal that encompasses all aspects of diagnosis, epidemiology, prevention and treatment of allergic and immunologic disease. By offering a high-visibility forum for new insights and discussions, AACI provides a platform for the dissemination of allergy and clinical immunology research and reviews amongst allergists, pulmonologists, immunologists and other physicians, healthcare workers, medical students and the public worldwide. AACI reports on basic research and clinically applied studies in the following areas and other related topics: asthma and occupational lung disease, rhinoconjunctivitis and rhinosinusitis, drug hypersensitivity, allergic skin diseases, urticaria and angioedema, venom hypersensitivity, anaphylaxis and food allergy, immunotherapy, immune modulators and biologics, immune deficiency and autoimmunity, T cell and B cell functions, regulatory T cells, natural killer cells, mast cell and eosinophil functions, complement abnormalities.
期刊最新文献
Introduction from the editors. Nasal food challenge with hen's egg white allergen. Inborn errors of immunity (primary immunodeficiencies). Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction. Retraction Note: Clinical and immuno-proteomic approach on lantana camara pollen allergy-a major health hazard.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1